Details of the Drug Combination

General Information of Drug Combination (ID: DC7CZNO)

• Drug Combination Name: Tremelimumab + MEDI0562
• Indication: Solid tumour/cancer; Status: Phase 1 [1]
• Component Drugs:
  Tremelimumab (DMOQ9H1): Monoclonal antibody
  MEDI0562 (DMYVBU6): N.A.

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Tremelimumab

Disease Entry	ICD 11	Status	REF
Hepatocellular carcinoma	2C12.02	Approved	[2]
Malignant mesothelioma	2C26.0	Phase 3	[3]
Solid tumour/cancer	2A00-2F9Z	Phase 3	[4]

Tremelimumab Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4)	TTI2S1D	CTLA4_HUMAN	Modulator	[6]

Indication(s) of MEDI0562

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]

MEDI0562 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
OX40L receptor (CD134)	TTL31H0	TNR4_HUMAN	Agonist	[5]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761289.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8462).
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).